NanoViricides, Inc. (NNVC:NYSEMKT) closed at $1.42 on November 10, 2026, up 6.77% on the day. The stock trades 26.4% below its 52-week high of $1.93 and 67.1% above its 52-week low of $0.850. Over the past year, it lost 10.7%. NanoViricides, Inc. is part of the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch).
In 252 trading sessions since November 10, 2025, NNVC closed higher on 105 days (42%). Its best day was September 21, 2026 (+19.01%) and its worst was May 15, 2026 (-14.94%). The stock moved 10% or more in a single session 18 times. It opened at least 5% above the previous day's high 3 times.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; anti-viral eye drops against external eye viral infections; and other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Find more stocks like NNVC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.